Carla Hausrath
Adult Health · Plattsburgh, NYNPI 1508095399
Payments from drug & device makers
Across 251 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$958
- Novo Nordisk$756
- AstraZeneca$331
- Lilly USA, LLC$320
- Pfizer$281
- GSK$236
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,17599%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $958 |
| Novo Nordisk | 39 | $756 |
| AstraZeneca | 18 | $331 |
| Lilly USA, LLC | 15 | $320 |
| Pfizer | 26 | $281 |
| GSK | 20 | $236 |
| Novartis | 8 | $184 |
| Johnson & Johnson | 6 | $138 |
| Amgen | 6 | $128 |
| Boehringer Ingelheim | 6 | $116 |
| Merck | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Dexcom, Inc. | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Lundbeck LLC | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Astellas Pharma US Inc | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Boston Scientific | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Abbott | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$4,198 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $128,087 |
| OzempicSemaglutide | 68 | $74,503 |
| FarxigaDapagliflozin Propanediol | 57 | $68,153 |
| JardianceEmpagliflozin | 66 | $65,004 |
| RybelsusSemaglutide | 52 | $62,334 |
| MyrbetriqMirabegron | 65 | $50,370 |
| TrulicityDulaglutide | 33 | $40,252 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $40,143 |
| MounjaroTirzepatide | 33 | $36,290 |
| XareltoRivaroxaban | 27 | $32,802 |
| JanuviaSitagliptin Phosphate | 18 | $22,780 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $18,874 |
| OxycontinOxycodone Hcl | 12 | $18,215 |
| TrintellixVortioxetine Hydrobromide | 33 | $17,162 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $17,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $756 | $136,837120 claims |
| PfizerEliquis | $281 | $128,087114 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $331 | $94,786120 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $320 | $76,54266 claims |
| Boehringer IngelheimJardiance | $116 | $65,00466 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $236 | $60,941101 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $50,37065 claims |
| Johnson & JohnsonXarelto | $138 | $32,80227 claims |
| MerckJanuvia | $77 | $22,78018 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $51 | $17,16233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.
Other adult health in Plattsburgh
- Jodi HamelPlattsburgh$17K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.